Loading clinical trials...

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT00811733

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent t...

Lead sponsor: GlaxoSmithKline•7 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

Not Yet RecruitingPhase 4

BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

NCT07474961 · Waldenstrom Macroglobulinaemia, Multiple Myeloma

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 30, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment37

Start dateMar 2009

Last updatedMay 30, 2017

Condition

Waldenstrom Macroglobulinaemia

Locations shown

GSK Investigational Site

Los Angeles, California

GSK Investigational Site

Stanford, California

GSK Investigational Site

Rochester, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 30, 2017Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

Trial snapshot

Condition

Locations shown

For caregivers